GlassScriptPhysician profile
Alejo Parellada
NPI 1417070442
$22,003.77
in general payments reported to CMS, 2019-2025
23 companies · $4,509 in 2025
The $4,509 reported for 2025 was more than what 90% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,463 · 2020: $1,220 · 2021: $2,389 · 2022: $2,771 · 2023: $4,017 · 2024: $4,636 · 2025: $4,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,939.25 |
| Education | $221.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $4,549.59 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $4,428.00 | 2021-2025 | |
| Alkermes, INC. | $3,459.20 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $2,472.61 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Lundbeck LLC | $1,604.14 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $1,110.84 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $539.60 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Idorsia Pharmaceuticals US INC | $538.83 | 2022-2024 | Quviviq |
| Allergan, INC. | $537.66 | 2019-2020 | |
| Axsome Therapeutics, INC. | $516.26 | 2024-2025 | Auvelity, Sunosi |
| Orexo US, INC. | $463.83 | 2019-2024 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $407.50 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $368.86 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $202.71 | 2021-2025 | Trintellix |
| Indivior INC. | $187.31 | 2019-2025 | Sublocade, Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $182.73 | 2020-2024 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.50 | 2019 | |
| Braeburn INC. | $105.69 | 2024-2025 | Brixadi |
| Mdd US Operations, LLC | $93.15 | 2019-2020 | |
| Noven Pharmaceuticals, INC. | $36.68 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $21.85 | 2022 | |
| Uswm, LLC | $18.25 | 2024 | Lucemyra |
| Sunovion Pharmaceuticals INC. | $15.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejo Parellada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.